New York, February 23, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Cell Therapy Market Forecast to 2027 – Impact of COVID-19 and Global Analysis by Type of Treatment; Product; Technology; Application ; end-user, and Geography “- https://www.reportlinker.com/p06027528/?utm_source=GNW
However, the high cost of manufacturing cell therapy is hindering the growth of the market.
Cell-to-cell surgery is a procedure in which live and intact cells are injected, inserted, or grafted into the patient’s body. This technology is responsible for the replacement of dysfunctional cells by healthy functioning cells.
Cells that are mainly used for advanced therapies are like cells, because they have the ability to differentiate into the specific cells that are essential for the repair of damaged or defective tissues or cells. In addition, cell therapy has applications in the development of regenerative medicine.
The biotechnology sector in Asia Pacific is growing supported by heavy investments and strategic developments between private and public organizations. For example, in December 2019, Astellas Pharma Inc. (Japan) signed an agreement to acquire Audentes Therapeutics Inc., a gene therapy company, for US $ 3 billion. Similarly, in November 2019, Fujifilm invested ~ US $ 120 million (JPY 13 billion) in gene therapy as part of the organization’s contract development and manufacturing division. In addition, the Japan Institute of Pharmaceutical Medical Equipment approved two gene therapy products. The results were simultaneously approved under the Sakigake specification, which is equivalent to the FDA’s breakthrough treatment specification and the EMA Priority Medicine (PRIME) specification and is expected to approve at least one treatment per year.
Such strategic developments by the domestic players in Asian countries for the field of cell therapy are likely to increase the demand for cell therapy in the future.Since Gendicine approval for the treatment of head-and-neck squamous cell carcinoma by replacing effect. replicas of the p53 tumor suppressor gene with standard gene replicas, China has expanded cell treatment applications and increased cell production.
Awareness is rising about cell therapy allowing an increase in the uptake of cell therapies in Asia Pacific.For example, in 2018, Taiwan held the ninth position for a regulatory body to approve a clinical application of cell therapy.
In January 2020, the country introduced six autologous therapies, which include two for cancer, two for skin cell remodeling, and two for bone and cartilage regeneration. In Taiwan, four hospitals have licenses to provide cell treatments, and a further 26 hospitals have already applied for a license to provide cell treatments.
In addition, regenerative medicine research in cell therapy, gene therapy, and tissue engineering is growing rapidly in Asian Pacific countries. Also, an increase in geriatric population; increase in improvements in healthcare services; increase in requirement for referral; and the emergence of personalized medicines in Japan, China, India and South Korea would create a demand for cellular therapies in the coming years. This is likely to provide various growth opportunities for the market players over the expected period.
The stem cell market, based on the type of treatment, is allogeneic and autologous.In 2019, the allogeneic sector accounted for a larger share due to the large number of permitted products available for clinical use.
For example, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic gas cell-based treatment approved for use in Europe.
The COVID-19 revolution was first reported in Wuhan (China) in December 2019. The pandemic is causing major upheavals in supply chains, consumer markets, and the world economy. .
As the healthcare sector aims to save the lives of COVID-19 patients, the demand for cell therapy is declining worldwide.
International Association of American College of Geology (ACC), World Health Organization (WHO), European Union (EU), Organization for Economic Co-operation and Development, Federal Commission para la Protección contra Riesgos Sanitarios (COFEPRIS), Ministry of Health and Prevention (MoHAP), and the U.S. Food and Drug Administration (FDA) are some of the top secondary sources cited during the preparation of the report on the cellular medicine market .
Read the full report: https://www.reportlinker.com/p06027528/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest business data so you can get all the market research you need – instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001